Activated cytotoxic T-lymphocyte immunotherapy is effective for advanced oral and maxillofacial cancers

International Journal of Oncology

Volumn 45, Issue 5, 2014, Pages 2051-2057

  Ohtani, Tomoko ^a   Yamada, Yoichi ^a   Furuhashi, Akifumi ^a   Ohmura, Yukinobu ^a   Nakamura, Sayaka ^a   Kato, Hidefumi ^a   Yoshikawa, Kazuhiro ^a,b   Kazaoka, Yoshiaki ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Adoptive immunotherapy; Cytotoxic T lymphocytes; Oral cancer; Quality of life; Treatment outcome

Indexed keywords

CYCLOPHOSPHAMIDE; GAMMA INTERFERON; HLA ANTIGEN CLASS 1;

ADULT; ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; FEMALE; FOLLOW UP; HELPER CELL; HISTOPATHOLOGY; HUMAN; LYMPHOCYTIC INFILTRATION; MALE; MAXILLOFACIAL CANCER; MAXILLOFACIAL DISORDER; MIDDLE AGED; MOUTH CANCER; MULTIMODALITY CANCER THERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; SPINDLE CELL SARCOMA; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE ACTIVATION; TREATMENT REFUSAL; TUMOR REGRESSION; TUMOR VOLUME; ADOPTIVE IMMUNOTHERAPY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MAXILLARY NEOPLASMS; MONONUCLEAR CELL; MOUTH NEOPLASMS; PATHOLOGY;

ADULT; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MAXILLARY NEOPLASMS; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM STAGING; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84907210011     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2599     Document Type: Article

References (22)

1. World Health Organization. The World Health Report 2004: Changing history. WHO, Geneva, 2004.
2. DeVita VT Jr and Rosenberg SA: Two hundred years of cancer research. N Engl J Med 366: 2207-2214, 2012.
3. Colevas AD: Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 10: 2644-2652, 2006.
4. Rosenberg SA, Lotze MT, Muul LM, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485-1492, 1985.
5. Ettinghausen SE , Puri RK and Rosenberg SA: Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. J Natl Cancer Inst 80: 177-188, 1988.
6. Soda H, Koda K, Yasutomi J, et al: Adoptive immunotherapy for advanced cancer patients using in vitro activated cytotoxic T lymphocytes. J Surg Oncol 72: 211-217, 1999.
7. Baxevanis CN, Dedoussis GV, Papadopoulos NG, Missitzis I, Stathopoulos GP and Papamichail M: Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer 74: 1275-1282, 1994.
8. Knuth A, Wolfel T and Meyer zum Buschenfelde KH: T cell responses to human malignant tumors. Cancer Surv 13: 39-52, 1992.
9. Desombere I, Meuleman P, Rigole H, et al: The interferon gamma secretion assay: A reliable tool to study interferon gamma production at the single cell level. J Immunol Methods 286: 167-185, 2004.
10. Straathof KC, Bollard CM, Popat U, et al: Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 105: 1898-1904, 2005.
11. Marijt E, Wafelman A, van der Hoorn M, et al: Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation. Haematologica 92: 72-80, 2007.
12. Toh U, Yamana H, Sueyoshi S, et al: Locoregional cellular immunotherapy for patients with advanced esophageal cancer. Clin Cancer Res 6: 4663-4673, 2000.
13. Yee C, Thompson JA, Byrd D, et al: Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 99: 16168-16173, 2002.
14. da Silva SD , Hier M, Mlynarek A, Kowalski LP and Alaoui-Jamali MA: Recurrent oral cancer: Current and emerging therapeutic approaches. Front Pharmacol 3: 149, 2012.
15. Kawakami Y, Eliyahu S, Delgado CH, et al: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 91: 3515-3519, 1994.
16. Saitoh S, Kurisaka M, Mori K, Maeda N and Fujimoto S: Induction of specific cytotoxic T lymphocytes against autologous brain tumor by crossreactive allo-tumor cell stimulation. Jpn J Cancer Res 88: 289-295, 1997.
17. Restifo NP, Dudley ME and Rosenberg SA: Adoptive immunotherapy for cancer: Harnessing the T cell response. Nat Rev Immunol 22: 269-281, 2012.
18. Rosenberg SA, Spiess P and Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318-1321, 1986.
19. Rosenberg SA, Yang JC, Sherry RM, et al: Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17: 4550-4557, 2011.
20. Khammari A, Nguyen JM, Pandolfino MC, et al: Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 56: 1853-1860, 2007.
21. Ratto GB, Zino P, Mirabelli S, et al: A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma. Cancer 78: 244-251, 1996.
22. Agra IM, Filho JG, Martins EP and Kowalski LP: Second salvage surgery for re-recurrent oral cavity and oropharynx carcinoma. Head Neck 32: 997-1002, 2010.